Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

▤ Summary

Quanterix completed its acquisition of Akoya Biosciences and combined the two companies into a larger life sciences platform. The deal expands Quanterix into blood-and-tissue biomarker solutions for neurology, oncology, and immunology. Quanterix said the transaction increases its served addressable market from $1 billion to $5 billion and supports a path to profitability by 2026. The company also updated its board and leadership structure as part of the closing.

▦ Linked Companies